Feldan Therapeutics, a Québec Metropolis, Québec, Canada-based early clinical-stage pharmaceutical firm, obtained an funding from Zynext Ventures.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to increase operations and its R&D efforts.
Led by CEO François-Thomas Michaud, Feldan is a clinical-stage pharmaceutical firm specializing within the improvement of remedies primarily based on the intracellular supply of therapeutics. Its proprietary peptide-based know-how, the Feldan Shuttle, allows the supply of antisense oligonucleotides into cells, producing new therapies.
Its lead product for BCC (FLD-103) is in a Part 1/2a medical trial, and the corporate’s pipeline enlargement is concentrated on pores and skin and lung ailments.
FinSMEs
17/04/2025
